Biosima
- Biotech or pharma, therapeutic R&D
BioSima, a biotech company founded in 2022 based in Brazil, has pioneered an innovative platform for developing exosome-based biopharmaceuticals. BioSima’s products are focused on addressing unmet medical needs by conventional therapies applied in Endocrinology (Diabetes), bone reconstruction (Orthopedics and Dentistry), and Neurology (Alzheimer's disease). BioSima’s biopharmaceuticals are developed utilizing cutting-edge R&D techniques applicable for regenerative medicine, employing exosome concentrates—nanometric extracellular vesicles produced naturally by living cells and concentrated through specific patented methods. Acting as active ingredients of biopharmaceuticals, these exosomes deliver their genetic and protein cargo to target local undifferentiated cells, aiming to stimulate their proliferative and differentiation potential for healing and repairing of diseased living tissues and organs.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}